CLINUVEL delivers increases in annual revenue, profit
Filed with ASX · · 4 pages · English
Clinuvel Pharmaceuticals Limited on 6ix
In the deck
Earlier from Clinuvel Pharmaceuticals
- Appendix 4E and Annual Report to Shareholders 2024
- Vitiligo and Operational Update
- Afamelanotide Assists DNA Repair Response Following UVR
- CLINUVEL extends Managing Director Employment Agreement
- afamelanotide in fair-skinned Parkinsons patients
Later from Clinuvel Pharmaceuticals
- Canadian New Drug Submission for SCENESSE in EPP filed
- Managing Director Presentation
- CLINUVEL prioritises three strategic programs
- SCENESSE dosage expansion under review by EMA
- Chair's letter to Shareholders
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals